A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

NCT05442684 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The trial protocol was not approved by the regulatory authorities.

Conditions

COVID-19

Interventions

BIOLOGICAL: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
BIOLOGICAL: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation
BIOLOGICAL: mRNA-based COVID-19 vaccine

Sponsor

CanSino Biologics Inc.